Chimerix Inc (CMRX) 4.08 $CMRX Chimerix to Announce

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chimerix Inc (CMRX) 4.08 $CMRX

Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Mon Aug 01, 7:00AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2016 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2016, and to provide a business overview.
CMRX: 4.08 (+0.09)

Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will participate in a panel focused on North Carolina's role in biodefense preparation at the "Medical, Biomedical and Biodefense: Support to the Warfighter Symposium" being held June 7-8, 2016 in Research Triangle Park, North Carolina.
CMRX: 4.08 (+0.09)

Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.69 (-0.06), CMRX: 4.08 (+0.09), LXRX: 16.72 (+0.40), INCY: 90.00 (-0.21)

Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 37.23 (+0.19), BLCM: 16.04 (+0.16), CMRX: 4.08 (+0.09)

Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 6:30AM CDT
- Maintains strong financial position with $314.5 million in capital at quarter end -
CMRX: 4.08 (+0.09)

Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Tue May 03, 5:00PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, May 9, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.
CMRX: 4.08 (+0.09)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.98 (+0.12), CMRX: 4.08 (+0.09), GERN: 2.71 (+0.03), CYTX: 2.17 (unch), CLDX: 4.67 (+0.05), SGMO: 6.61 (+0.28), PTCT: 6.10 (+0.13), ATHX: 2.17 (-0.05), MNKD: 1.02 (+0.03)

Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX
ACCESSWIRE - Tue Mar 22, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Despite the challenges that continue to press the Biotech industry, ValuableInvestment.com, this morning, turns its focus on the following Healthcare companies: Celgene Corp. (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Exelixis Inc. (NASDAQ: EXEL), and Chimerix Inc. (NASDAQ: CMRX). Find out why these stocks are under our microscope by clicking the link below:
CMRX: 4.08 (+0.09), ARIA: 9.71 (+0.20), EXEL: 9.27 (+0.09), CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)

Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.24 (unch), INO: 10.42 (+0.54), CMRX: 4.08 (+0.09), ORPN: 1.62 (-0.10), BLRX: 0.76 (-0.02)

Chimerix to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Wed Mar 09, 7:30AM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson, Chief Commercial Officer of Chimerix, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 2:35 p.m. ET at the Loews Miami Beach Hotel in Miami, FL.
CMRX: 4.08 (+0.09)

A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 125.40 (+0.17), CMRX: 4.08 (+0.09), MRK: 58.66 (unch), CDTX: 11.95 (+0.06), GSK: 45.25 (+0.18)

Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
GlobeNewswire - Mon Feb 08, 1:03PM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today presented positive results from a pivotal study of its antiviral, brincidofovir, in an animal model for smallpox at the ASM Biodefense and Emerging Diseases Research Meeting in Arlington, Virginia.
CMRX: 4.08 (+0.09)

Latest Global Chimerix, Inc. Market Research Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:12AM CST
'CHIMERIX, INC. - Product Pipeline Review - 2015', provides an overview of the CHIMERIX, INC.'s pharmaceutical research and development focus.
CMRX: 4.08 (+0.09)

WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
ACCESSWIRE - Wed Feb 03, 8:22AM CST
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT" , an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected.
INO: 10.42 (+0.54), BCRX: 3.70 (+0.08), CMRX: 4.08 (+0.09), XON: 27.38 (+2.05)

Chimerix Inc. Is Roaring Higher Again -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 20, 2:54PM CST
What:  Investors in  Chimerix  managed to buck the market wide sell-off today as shares of the clinical-stage biopharma jumped more than 13% as of 2:50 p.m. ET after an analyst published a bullish forecast for the company's stock.  So what: ...
CMRX: 4.08 (+0.09), XBI: 63.57 (+1.50)

Strength Seen in Chimerix (CMRX): Stock Rises 8.1%
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 7:00AM CST
Chimerix (CMRX) was a big mover last session, with its shares rising just over 8% on the day.
CMRX: 4.08 (+0.09), ABAX: 49.14 (-0.32)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 119.55 (+0.17), VICL: 4.25 (+0.10), CMRX: 4.08 (+0.09), PFE: 37.31 (+0.42), MRK: 58.66 (unch), ATRA: 24.40 (+0.40), VBIV: 3.79 (-0.01), GSK: 45.25 (+0.18), NVS: 83.07 (-0.19)

4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 0.46 (-0.03), TMST: 9.02 (-1.00), CMRX: 4.08 (+0.09), AEZS: 3.44 (+0.07)

Why Chimerix Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jan 19, 11:50AM CST
What:  Shares of  Chimerix  , a clinical-stage biopharma focused on antiviral drugs, rose more than 13% as of 11:15 a.m. ET.  So what:  There doesn't appear to be any news today to justify the strong share price move, so it's likely that shares...
ESPR: 10.98 (+0.12), CMRX: 4.08 (+0.09)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 68

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 80

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 160

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

B. Riley Financial Partners with Oaktree to Enhance Services

Updated Category News Views 55

B. Riley Financial and Oaktree: A Strategic Collaboration B. Riley Financial, Inc. (NASDAQ: RILY) is thrilled to announce a new partnership with Oaktree Capital Management, L.P. to strengthen its Great American Group businesses. Definitive Agreement Signed The companies have finalized a definitive agreement enabling a collaboration through a newly formed holding company...

Continue Reading
General Motors Faces Changes: A Shift in EV Incentive Strategy

Updated Category News Views 348

General Motors Adjusts EV Incentives General Motors Co. (NYSE: GM) has decided to revise its plans concerning electric vehicle (EV) incentives after initially suggesting options beyond the Federal EV Credit deadline. This shift comes shortly after rising scrutiny from political figures around the implications of such financial strategies. Concerns Raised by Key...

Continue Reading
Pacsun Unveils Stylish New Sunglasses Collection for All

Updated Category News Views 327

Pacsun Launches an Elegant Sunglass Collection Pacsun has taken a bold step in expanding its product range by introducing a new collection of premium sunglasses. This unisex line represents the brand's commitment to elevating its accessory offerings, appealing to a broader audience of style-conscious consumers. Innovative Designs in Sunglass Fashion With the release of...

Continue Reading
Exploring the Rapid Growth of the Opioid Use Disorder Market

Updated Category News Views 216

Understanding the Opioid Use Disorder Market and Its Promising Growth The opioid crisis represents a major public health challenge, significantly impacting communities across the globe. According to research, the Opioid Use Disorder Market was evaluated at approximately USD 3.7 billion recently, with an exciting projection to surge to USD 9.02 billion by 2032. This...

Continue Reading
Artea Bankas Secures ECB Approval for Stock Buyback Initiative

Updated Category News Views 242

Artea Bankas Secures ECB Approval for Stock Buyback Initiative AB Artea Bankas has recently gained essential approval from the European Central Bank (ECB) allowing the bank to buy back up to 4,500,000 of its own shares, marking a significant step in enhancing shareholder value. This buyback program is anticipated to commence within one year, demonstrating the bank's...

Continue Reading